{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:50:32Z","timestamp":1793260232908,"version":"4.5.0"},"reference-count":41,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2024,10,21]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>The optimal timing for initiating direct oral anticoagulants (DOACs) for secondary stroke prevention in patients with atrial fibrillation and acute ischaemic stroke remains controversial due to concerns about haemorrhagic transformation. This study aimed to analyse the efficacy and safety of early versus late DOAC initiation. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review was conducted, searching major databases (PubMed, Embase, Cochrane Library and ClinicalTrials.gov) up to May 2024. A total of 11 studies were identified, comprising nine cohort studies (75.5% weight) and two randomised controlled trials (RCTs) (24.5% weight), involving 13\u2009020 participants. The early DOAC group (mean initiation 3.5\u00b11.29\u2009days) included 6250 participants, while the late group (5.7\u00b11.25\u2009days) had 6770 participants. Outcome measures included recurrent ischaemic stroke (RIS), intracranial haemorrhage (ICH), systemic embolism, major haemorrhage (MH), non-major haemorrhage (NMH) and all-cause mortality. Statistical analysis using the Cochrane Review Manager calculated ORs and 95% CIs via the Mantel-Haenszel random effects model. This pooled meta-analysis revealed that the early DOAC group had lower rates of RIS (2.2% vs 2.9%, OR 0.72, 95% CI 0.52 to 0.98, p=0.04, I<jats:sup>2<\/jats:sup>=40%) and ICH (0.51% vs 0.93%, OR 0.45, 95% CI 0.29 to 0.70, p&lt;0.05, I<jats:sup>2<\/jats:sup>=0%) compared with the late DOAC group. Subgroup analysis of RCTs and cohort studies showed reduced RIS and ICH risks in the early DOAC group, with moderate heterogeneity. In the sensitivity analysis, the early group (&lt;4\u2009days) had a lower risk of RIS compared with the late group (&gt;4\u2009days) without a statistically significant impact on ICH. No significant differences in MH, NMH, systemic embolism or all-cause mortality were observed between either group; however, a limited number of RCTs and moderate heterogeneity weakened the conclusions. Additional RCTs are needed to provide more definitive insights.<\/jats:p>","DOI":"10.1136\/openhrt-2024-003002","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:15:35Z","timestamp":1732767335000},"page":"e003002","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Optimal timing of oral anticoagulation initiation in patients with acute ischaemic stroke and atrial fibrillation: a comprehensive meta-analysis and systematic review"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03021928","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06057467","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7689-3750","authenticated-orcid":false,"given":"Aravind","family":"Dilli Babu","sequence":"first","affiliation":[{"name":"Internal Medicine, Sinai Hospital (LifeBridge Health), Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahib","family":"Singh","sequence":"additional","affiliation":[{"name":"Internal Medicine, Sinai Hospital (LifeBridge Health), Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Gorantla","sequence":"additional","affiliation":[{"name":"Cardiology, SUNY Downstate Medical Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Faris","family":"Ali Baig","sequence":"additional","affiliation":[{"name":"Internal Medicine, Asante Three Rivers Medical Center, Grants Pass, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Internal Medicine, Sinai Hospital (LifeBridge Health), Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harika","family":"Davuluri","sequence":"additional","affiliation":[{"name":"Internal Medicine, Sinai Hospital (LifeBridge Health), Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekshminarayan","family":"Raghavakurup","sequence":"additional","affiliation":[{"name":"Internal Medicine, Sinai Hospital (LifeBridge Health), Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Herweg","sequence":"additional","affiliation":[{"name":"Electrophysiology, University of South Florida, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025081709272168000_11.2.e003002.1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"2025081709272168000_11.2.e003002.2","doi-asserted-by":"crossref","unstructured":"Virani SS , Alonso A , Benjamin EJ , et al . Heart Disease and Stroke statistics\u20142020 Update. Circulation 2020;141. doi:10.1161\/CIR.0000000000000757","DOI":"10.1161\/CIR.0000000000000757"},{"key":"2025081709272168000_11.2.e003002.3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"The Lancet"},{"key":"2025081709272168000_11.2.e003002.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000254600.92975.1f"},{"key":"2025081709272168000_11.2.e003002.5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.703258","article-title":"Hemorrhagic Transformation After Ischemic Stroke: Mechanisms and Management","volume":"12","author":"Hong","year":"2021","journal-title":"Front Neurol"},{"key":"2025081709272168000_11.2.e003002.6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"2025081709272168000_11.2.e003002.7","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2013.00069","article-title":"Hemorrhagic transformation: a review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke","volume":"4","author":"Sussman","year":"2013","journal-title":"Front Neurol"},{"key":"2025081709272168000_11.2.e003002.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303048"},{"key":"2025081709272168000_11.2.e003002.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060666"},{"key":"2025081709272168000_11.2.e003002.10","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00415-021-10788-z","article-title":"Early anticoagulation in atrial fibrillation-related acute ischaemic stroke: efficacy and safety profile","volume":"269","author":"Matos-Ribeiro","year":"2022","journal-title":"J Neurol"},{"key":"2025081709272168000_11.2.e003002.11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007034","article-title":"Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study","volume":"6","author":"Paciaroni","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025081709272168000_11.2.e003002.12","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.008891"},{"key":"2025081709272168000_11.2.e003002.13","doi-asserted-by":"crossref","unstructured":"Singh S , Tantry U , Ashley WW , et al . Abstract 14464: Meta-Analysis Comparing Early vs Delayed Anticoagulation After Stroke in Patients With Atrial Fibrillation. Circulation 2023;148. doi:10.1161\/circ.148.suppl_1.14464","DOI":"10.1161\/circ.148.suppl_1.14464"},{"key":"2025081709272168000_11.2.e003002.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht134"},{"key":"2025081709272168000_11.2.e003002.15","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2025081709272168000_11.2.e003002.16","doi-asserted-by":"crossref","first-page":"116582","DOI":"10.1016\/j.jns.2019.116582","article-title":"Timing to start anticoagulants after acute ischemic stroke with non-valvular atrial fibrillation","volume":"409","author":"Al Bakr","year":"2020","journal-title":"J Neurol Sci"},{"key":"2025081709272168000_11.2.e003002.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1393-9"},{"key":"2025081709272168000_11.2.e003002.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327236"},{"key":"2025081709272168000_11.2.e003002.19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25844"},{"key":"2025081709272168000_11.2.e003002.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318890"},{"key":"2025081709272168000_11.2.e003002.21","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2023-002357"},{"key":"2025081709272168000_11.2.e003002.22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/2396987320937116","article-title":"Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes","volume":"5","author":"Paciaroni","year":"2020","journal-title":"Eur Stroke J"},{"key":"2025081709272168000_11.2.e003002.23","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.028118"},{"key":"2025081709272168000_11.2.e003002.24","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.06.031","article-title":"Early Initiation of Anticoagulation with Direct Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke","volume":"25","author":"Macha","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2025081709272168000_11.2.e003002.25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/STROKEAHA.121.036695","article-title":"Practical '1-2-3-4-Day' Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: combined Hospital-Based Cohort Study","volume":"53","author":"Kimura","year":"2022","journal-title":"Stroke"},{"key":"2025081709272168000_11.2.e003002.26","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1177\/17474930231184366","article-title":"Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study","volume":"18","author":"Grosse","year":"2023","journal-title":"Int J Stroke"},{"key":"2025081709272168000_11.2.e003002.27","doi-asserted-by":"crossref","first-page":"105893","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105893","article-title":"Anticoagulation Protocol for Secondary Prevention of Acute Ischemic Stroke Associated with Nonvalvular Atrial Fibrillation","volume":"30","author":"Kimura","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2025081709272168000_11.2.e003002.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212354","article-title":"Rivaroxaban administration after acute ischemic stroke: The RELAXED study","volume":"14","author":"Yasaka","year":"2019","journal-title":"PLoS One"},{"key":"2025081709272168000_11.2.e003002.29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.0000000000003283","article-title":"Early start of DOAC after ischemic stroke","volume":"87","author":"Seiffge","year":"2016","journal-title":"Neurology (ECronicon)"},{"key":"2025081709272168000_11.2.e003002.30","unstructured":"Copenhagen: the Cochrane Collaboration . Review manager 5 (revman 5) [computer program]. version 5.4. Copenhagen: the Cochrane Collaborationp; 2020."},{"key":"2025081709272168000_11.2.e003002.31","unstructured":"Wells G , Shea B , O\u2019Connell D , et al . The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. Wwwohrica; 2021. Available: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2025081709272168000_11.2.e003002.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025081709272168000_11.2.e003002.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025081709272168000_11.2.e003002.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025081709272168000_11.2.e003002.35","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1253\/circj.CJ-18-0067","article-title":"Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation - SAMURAI-NVAF Study","volume":"82","author":"Yoshimura","year":"2018","journal-title":"Circ J"},{"key":"2025081709272168000_11.2.e003002.36","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S121661"},{"key":"2025081709272168000_11.2.e003002.37","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025081709272168000_11.2.e003002.38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11239-023-02872-0","article-title":"Comparison of early and delayed anticoagulation therapy after ischemic stroke in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"56","author":"Jiang","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2025081709272168000_11.2.e003002.39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030380","article-title":"Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials","volume":"12","author":"Lin","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025081709272168000_11.2.e003002.40","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025081709272168000_11.2.e003002.41","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;71. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2024-003002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:27:31Z","timestamp":1755448051000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2024-003002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/openhrt-2024-003002"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2024-003002","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}